Application
RAVER1 Antibody (N-term) western blot analysis in HL-60 cell line lysates (35ug/lane).This demonstrates the RAVER1 antibody detected the RAVER1 protein (arrow).| Product Name | RAVER1 Antibody (N-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | RAVER1; KIAA1978; Ribonucleoprotein PTB-binding 1; Protein raver-1 |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WB |
| WB:1:100~500 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | KIAA1978 |
|---|---|
| Alternative Names | RAVER1 KIAA1978 Ribonucleoprotein PTB-binding 1 Protein raver-1 |
| Molecular Weight(MW) | 63877 Da |
| Function | Cooperates with PTBP1 to modulate regulated alternative splicing events. Promotes exon skipping. Cooperates with PTBP1 to modulate switching between mutually exclusive exons during maturation of the TPM1 pre-mRNA (By similarity) |
| Tissue Specificity | This RAVER1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 55-83 amino acids from the N-terminal region of human RAVER1. |
| Cellular Localization | Nucleus (By similarity). Cytoplasm (By similarity). Note=Nuclear, in perinucleolar structures. Shuttles between nucleus and cytoplasm. Cytoplasm, at focal contacts and cell-cell contacts. Associated with myotubes during muscle differentiation (By similarity) |
| Entrez Gene | 125950 |
|---|---|
| Nucleotide Accession | NP_597709.2 |
Application
RAVER1 Antibody (N-term) western blot analysis in HL-60 cell line lysates (35ug/lane).This demonstrates the RAVER1 antibody detected the RAVER1 protein (arrow).| Application Notes | WB:1:100~500 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
